Finland's Orion Corporation is considering putting up $26 million to fund a new Phase III trial of the heart failure drug Simdax. Orion officials announced that they are in talks with Abbott Laboratories about the further testing of the therapy. Both companies plan discussions with the FDA over the trial, set to begin in March.
- check out this press release for more
- here's the report on Orion from ABC Money
Orion ponders new Phase III for Simdax. Report